{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:39:20Z","timestamp":1777527560537,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-674","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T07:01:35Z","timestamp":1410937295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice"],"prefix":"10.1186","volume":"14","author":[{"given":"Mark","family":"Linch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Gennatas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Kazikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhangir","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranga","family":"Gunapala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Priest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Severn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bee","family":"Ayite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishree","family":"Bhosle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"issue":"3","key":"4881_CR1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","volume":"92","author":"JT Hodgson","year":"2005","unstructured":"Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J: The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005, 92 (3): 587-593.","journal-title":"Br J Cancer"},{"issue":"15","key":"4881_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA: Advances in malignant mesothelioma. N Engl J Med. 2005, 353 (15): 1591-1603. 10.1056\/NEJMra050152.","journal-title":"N Engl J Med"},{"issue":"6","key":"4881_CR3","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/1078-0432.CCR-11-1808","volume":"18","author":"BM Burt","year":"2012","unstructured":"Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ: Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012, 18 (6): 1568-1577. 10.1158\/1078-0432.CCR-11-1808.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4881_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e3182417da5","volume":"7","author":"G Levallet","year":"2012","unstructured":"Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, Pairon JC, Bergot E, Zalcman G, Galateau-Salle F: Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol. 2012, 7 (3): 599-606. 10.1097\/JTO.0b013e3182417da5.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4881_CR5","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/cncr.26497","volume":"118","author":"SC Kao","year":"2012","unstructured":"Kao SC, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, Wilson A, Henderson DW, Klebe S: Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer. 2012, 118 (11): 2952-2961. 10.1002\/cncr.26497.","journal-title":"Cancer"},{"issue":"11","key":"4881_CR6","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","volume":"6","author":"SC Kao","year":"2011","unstructured":"Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B: Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011, 6 (11): 1923-1929. 10.1097\/JTO.0b013e31822a3740.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"4881_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2217\/14622416.9.8.1069","volume":"9","author":"A Baldi","year":"2008","unstructured":"Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chein J, Shridhar V, Ehrmann M, Santini M, Facciolo F: The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics. 2008, 9 (8): 1069-1077. 10.2217\/14622416.9.8.1069.","journal-title":"Pharmacogenomics"},{"issue":"8","key":"4881_CR8","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","volume":"18","author":"C Plathow","year":"2008","unstructured":"Plathow C, Klopp M, Thieke C, Herth F, Thomas A, Schmaehl A, Zuna I, Kauczor HU: Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol. 2008, 18 (8): 1635-1643. 10.1007\/s00330-008-0918-9.","journal-title":"Eur Radiol"},{"issue":"2","key":"4881_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004, 15 (2): 257-260. 10.1093\/annonc\/mdh059.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"4881_CR10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.lungcan.2005.03.009","volume":"49","author":"JP Steele","year":"2005","unstructured":"Steele JP, Klabatsa A, Fennell DA, Pallaska A, Sheaff MT, Evans MT, Shamash J, Rudd RM: Prognostic factors in mesothelioma. Lung Cancer. 2005, 49 (Suppl 1): S49-S52.","journal-title":"Lung Cancer"},{"issue":"2","key":"4881_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","volume":"256","author":"B Ghanim","year":"2012","unstructured":"Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, Pohl W, Zielinski C, Filipits M, Klepetko W, Berger W: Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg. 2012, 256 (2): 357-362. 10.1097\/SLA.0b013e3182602af4.","journal-title":"Ann Surg"},{"issue":"3","key":"4881_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.113.3.723","volume":"113","author":"JE Herndon","year":"1998","unstructured":"Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998, 113 (3): 723-731. 10.1378\/chest.113.3.723.","journal-title":"Chest"},{"issue":"10","key":"4881_CR13","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","volume":"13","author":"BD Grigoriu","year":"2007","unstructured":"Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007, 13 (10): 2928-2935. 10.1158\/1078-0432.CCR-06-2144.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4881_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","volume":"367","author":"HI Pass","year":"2012","unstructured":"Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012, 367 (15): 1417-1427. 10.1056\/NEJMoa1115050.","journal-title":"N Engl J Med"},{"issue":"17","key":"4881_CR15","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","volume":"13","author":"A Cristaudo","year":"2007","unstructured":"Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007, 13 (17): 5076-5081. 10.1158\/1078-0432.CCR-07-0629.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4881_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","volume":"53","author":"HL Beyer","year":"2007","unstructured":"Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY: MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007, 53 (4): 666-672. 10.1373\/clinchem.2006.079327.","journal-title":"Clin Chem"},{"issue":"1","key":"4881_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","volume":"85","author":"HI Pass","year":"2008","unstructured":"Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008, 85 (1): 265-272. 10.1016\/j.athoracsur.2007.07.042. discussion 272","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"4881_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1183\/09031936.00226111","volume":"41","author":"I Pantazopoulos","year":"2013","unstructured":"Pantazopoulos I, Boura P, Xanthos T, Syrigos K: Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013, 41 (3): 706-715. 10.1183\/09031936.00226111.","journal-title":"Eur Respir J"},{"issue":"4","key":"4881_CR19","doi-asserted-by":"publisher","first-page":"e33214","DOI":"10.1371\/journal.pone.0033214","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F: Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012, 7 (4): e33214-10.1371\/journal.pone.0033214.","journal-title":"PLoS One"},{"issue":"2","key":"4881_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","volume":"6","author":"N Uehara","year":"2008","unstructured":"Uehara N, Matsuoka Y, Tsubura A: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res. 2008, 6 (2): 186-193. 10.1158\/1541-7786.MCR-07-0254.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"4881_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","volume":"11","author":"RJ Kelly","year":"2012","unstructured":"Kelly RJ, Sharon E, Pastan I, Hassan R: Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther. 2012, 11 (3): 517-525. 10.1158\/1535-7163.MCT-11-0454.","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"4881_CR22","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","volume":"28","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O\u2019Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G: Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010, 28 (20): 3316-3322. 10.1200\/JCO.2009.26.9944.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4881_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1556-0864(15)31535-5","volume":"1","author":"J Creaney","year":"2006","unstructured":"Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW: Soluble mesothelin related protein in mesothelioma. J Thorac Oncol. 2006, 1 (2): 172-174. 10.1097\/01243894-200602000-00013.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4881_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","volume":"179","author":"BD Grigoriu","year":"2009","unstructured":"Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A: Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med. 2009, 179 (10): 950-954. 10.1164\/rccm.200807-1125OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4881_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","volume":"17","author":"J Creaney","year":"2011","unstructured":"Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK: Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2011, 17 (5): 1181-1189. 10.1158\/1078-0432.CCR-10-1929.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4881_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/A:1008236010868","volume":"9","author":"GW Middleton","year":"1998","unstructured":"Middleton GW, Smith IE, O\u2019Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998, 9 (3): 269-273. 10.1023\/A:1008236010868.","journal-title":"Ann Oncol"},{"issue":"14","key":"4881_CR27","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21 (14): 2636-2644. 10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4881_CR28","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/S0169-5002(05)80928-6","volume":"49","author":"N Vogelzang","year":"2005","unstructured":"Vogelzang N, Symanowski J, Rusthoven J, Manegold C, Boyer M, Nguyen B, Paoletti P: Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer. 2005, 49 (2): S230-S231.","journal-title":"Lung Cancer"},{"issue":"24","key":"4881_CR29","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D: Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010, 16 (24): 6132-6138. 10.1158\/1078-0432.CCR-10-2275.","journal-title":"Clin Cancer Res"},{"key":"4881_CR30","first-page":"3235","volume":"2","author":"C Rao","year":"2009","unstructured":"Rao C, Huber M, Vemuri K, Zhang Q, Chen B, Phillips J, Greenbaum M, Sung J, Derwin D, Passmore D, Vangipuram R, Terrett J, Deshpande S, Cardarelli P, Blanset D, Gangwar S: Abstract #3235: Efficacy and toxicity of an anti-mesothelin antibody drug conjugate. Proc 100th Annu Meet Am Assoc Canc Res. 2009, 2: 3235-","journal-title":"Proc 100th Annu Meet Am Assoc Canc Res"},{"issue":"3","key":"4881_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","volume":"18","author":"DT Le","year":"2012","unstructured":"Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru AD: A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012, 18 (3): 858-868. 10.1158\/1078-0432.CCR-11-2121.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4881_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2217\/imt.12.91","volume":"4","author":"C Colovos","year":"2012","unstructured":"Colovos C, Villena-Vargas J, Adusumilli PS: Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Immunotherapy. 2012, 4 (9): 899-902. 10.2217\/imt.12.91.","journal-title":"Immunotherapy"},{"issue":"14","key":"4881_CR33","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM: Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011, 17 (14): 4719-4730. 10.1158\/1078-0432.CCR-11-0351.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4881_CR34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","volume":"6","author":"A Cristaudo","year":"2011","unstructured":"Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R: Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol. 2011, 6 (9): 1587-1593. 10.1097\/JTO.0b013e31821e1c08.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4881_CR35","first-page":"145","volume":"5","author":"T Mori","year":"2013","unstructured":"Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K: The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis. 2013, 5 (2): 145-148.","journal-title":"J Thorac Dis"},{"issue":"3","key":"4881_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.lungcan.2011.01.011","volume":"73","author":"N Boudville","year":"2011","unstructured":"Boudville N, Paul R, Robinson BW, Creaney J: Mesothelin and kidney function\u2013analysis of relationship and implications for mesothelioma screening. Lung Cancer. 2011, 73 (3): 320-324. 10.1016\/j.lungcan.2011.01.011.","journal-title":"Lung Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-674\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:51:30Z","timestamp":1630561890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4881"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-674","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,17]]},"assertion":[{"value":"9 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"674"}}